Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluvoxamine Clear all
Completed Phase 2 Interventional Results available

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

NCT03222570
View directory record Official record
Conditions
Depressive Disorder
Interventions
Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
Behavioral · Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Fluvoxamine for Long COVID-19

NCT05874037
View directory record Official record
Conditions
Long COVID
Interventions
Fluvoxamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Not applicable Interventional Results available

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

NCT02655354
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions
Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

NCT05894564
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
103
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

NCT06821698
View directory record Official record
Conditions
Healty Volunteers
Interventions
KP-001, Rosuvastatin calcium10mg, Caffeine citrate, Fluvoxamine
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 16, 2026, 10:49 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)

NCT00743834
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Luvox CR, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Rogers Center for Research & Training, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

NCT01540500
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Fluvoxamine
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

NCT03930602
View directory record Official record
Conditions
Healthy
Interventions
BMS-986165, Fluvoxamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Withdrawn Phase 2 Interventional

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

NCT05216614
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Parosmia
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03432793
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
TD-9855, Fluvoxamine, Itraconazole, Caffeine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

NCT05712265
View directory record Official record
Conditions
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant, Fluvoxamine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
dovitinib (TKI258), fluvoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 16, 2026, 10:49 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 16, 2026, 10:49 PM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

NCT01299415
View directory record Official record
Conditions
Solid Tumors
Interventions
Vadimezan™
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 16, 2026, 10:49 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Recruiting Phase 3 Interventional

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

NCT06969287
View directory record Official record
Conditions
Delirium, Surgery-Complications
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

NCT04342663
View directory record Official record
Conditions
COVID 19, Coronavirus
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Belleville, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

NCT03340662
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-122, Itraconazole, Fluvoxamine, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01707407
View directory record Official record
Conditions
Pharmacology, Clinical, Healthy
Interventions
Pomalidomide, Ketoconazole, Fluvoxamine, Carbamazepine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 16, 2026, 10:49 PM EDT